ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

ZAS (Ziekenhuis aan de Stroom) at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

ZAS (Ziekenhuis aan de Stroom) takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions focus on treatment and outcomes in early and advanced triple-negative breast cancer. They examine blood metabolites as possible indicators of chemotherapy response and compare sacituzumab govitecan with chemotherapy in previously untreated advanced disease.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
General hospital network with several campuses in Antwerp, Belgium.
Satellite
Sat Oct 24
13:00–13:15
Chair Introduction: Urgency to treat in 1L mTNBC: The 1L population and Treatment goals
Gilead and Kite Oncology - Sacituzumab Govitecan (SG), new backbone for 1L mTNBC, regardless of PD-L1 status. Changing the 1L paradigm: what the new indication approvals mean for everyday clinical practice
Breast cancer
Satellite
Sat Oct 24
14:05–14:30
Tomorrow in the clinic: Chair-led discussion
Gilead and Kite Oncology - Sacituzumab Govitecan (SG), new backbone for 1L mTNBC, regardless of PD-L1 status. Changing the 1L paradigm: what the new indication approvals mean for everyday clinical practice
Breast cancer

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at ZAS (Ziekenhuis aan de Stroom)

Tell us what you sell and we’ll find the people at ZAS (Ziekenhuis aan de Stroom) most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction